AMPH
Strong BuyFull HouseAI neutralAmphastar Pharmaceuticals, Inc. · Healthcare · United States · $1.1B cap · $12.3M/day traded
$25.47 +1.3% · close 26 Oct · scored 27 Oct
StockRank down 1.3 since 24 Oct: Momentum down 3.
Full House: Strong business, sensible price, market agrees. The rare full house.
As of 27 Oct 2026, MoatMap's StockRank for Amphastar Pharmaceuticals, Inc. (AMPH) is 93/100, ranked against 24,000+ stocks in 35 markets (Quality 61, Value 73, Momentum 64, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Amphastar makes complex generic injectables, inhalation products and branded items such as its nasal glucagon. It is profitable and is buying back shares, but recent news flow is routine (conference appearances, Q2 results) and BofA has cut ratings across a group of biopharma names on valuation and catalyst concerns. Insiders have sold a small amount of stock. There is no clear catalyst that the current share price obviously misses.
The ranks quoted here are from the day it was written; today's Quality, Value and Momentum are the bars above.
ABOUT AMPHASTAR PHARMACEUTICALS, INC.
Read
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and markets injectable, intranasal, and inhalation products, focusing on complex generics and proprietary drugs. The company's competitive advantage lies in its expertise with difficult-to-manufacture sterile products and a robust pipeline of both generic and branded pharmaceuticals. It leverages a vertically integrated structure to control critical raw material supply and manufacturing processes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 499.0M | 644.4M | 732.0M | 719.9M | 13.0% | 730.0M | 747.3M | 784.0M | 4.4% |
| EPS | 1.88 | 2.85 | 3.29 | 2.10 | 3.8% | 1.69 | 1.91 | 2.33 | 5.3% |
| Shares | 48.1M | 48.1M | 47.6M | 45.6M | -5.1% | 42.5M | — | — | — |
| Debt | 102.6M | 623.6M | 650.5M | 656.0M | 85.6% | 688.3M | — | — | — |
| Equity | 528.7M | 639.4M | 732.3M | 788.8M | 14.3% | — | — | — | — |
| Op CF | 89.2M | 183.5M | 213.4M | 156.1M | 20.5% | 184.6M | — | — | — |
| Inv CF | -32.8M | -649.1M | -124.9M | -70.3M | — | — | — | — | — |
| Fin CF | -26.4M | 454.1M | -81.0M | -67.4M | — | — | — | — | — |
Above its 200-day average and 14% below its 52-week high.
Swung more than 65% of stocks we rank over the past year (51% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMPH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals, Inc.(you) | $1.1B | 93 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.4B | 89 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.5B | 90 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 89 | Strong Buy |
| IRWD | Ironwood Pharmaceuticals, Inc. | $572M | 99 | Strong Buy |
| COLL | Collegium Pharmaceutical, Inc. | $747M | 82 | Strong Buy |
| TRLV | Trulieve Cannabis Corp. | $2.0B | 80 | Buy |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 90 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.0B | 74 | Buy |
| PAHC | Phibro Animal Health Corporation | $1.6B | 63 | Hold |
Peer medians: ROE -30.5% · P/E 27.3x · Gross margin 63.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.